Related Experiment Video

Updated: Aug 12, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 24, 2014

PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome

Reinout Raijmakers1, Manfred Renz, Claudia Wiemann

  • 1University of Nijmegen, Nijmegen, The Netherlands.

Arthritis and Rheumatism
|February 12, 2004
PubMed
Abstract

Insights

The longer PM-Scl-75 protein isoform is a more sensitive marker for detecting anti-PM-Scl autoantibodies in polymyositis/scleroderma overlap syndrome patients. This enhanced detection aids in diagnosing this autoimmune condition.

Area of Science:

  • Immunology
  • Autoimmune Diseases
  • Protein Biochemistry

Background:

  • Polymyositis (PM)/scleroderma overlap syndrome is an autoimmune condition characterized by overlapping features of polymyositis and scleroderma.
  • Anti-PM-Scl autoantibodies are important serological markers for diagnosing PM/scleroderma overlap syndrome.
  • The PM-Scl autoantigen exists in different protein isoforms, including PM-Scl-100 and PM-Scl-75.

Purpose of the Study:

  • To compare the autoantigenicity of the N-terminally elongated PM-Scl-75 protein with PM-Scl-100 and the original PM-Scl-75.
  • To evaluate the diagnostic utility of the longer PM-Scl-75 isoform for analyzing sera from patients with PM/scleroderma overlap syndrome.

Main Methods:

  • Serum samples from patients with PM/scleroderma overlap syndrome and other diseases were analyzed.
  • Enzyme-linked immunosorbent assay (ELISA) was used to detect autoantibodies against recombinant PM-Scl-100 and PM-Scl-75 (original and longer forms).

Main Results:

  • Autoantibodies against the longer PM-Scl-75 isoform were found in 28% of PM/scleroderma patients, higher than PM-Scl-100 (25%) and original PM-Scl-75 (11%).
  • A significant number of patients showed anti-PM-Scl-75 antibodies without anti-PM-Scl-100 antibodies, contrasting previous findings for the shorter PM-Scl-75 version.

Conclusions:

  • The longer PM-Scl-75 isoform significantly enhances the detection rate of anti-PM-Scl autoantibodies in patients with PM/scleroderma overlap syndrome.
  • Incorporating the long PM-Scl-75 isoform alongside PM-Scl-100 in ELISAs improves serological diagnosis for this autoimmune condition.

More Related Videos

In Situ Detection of Autoreactive CD4 T Cells in Brain and Heart Using Major Histocompatibility Complex Class II Dextramers13:10

In Situ Detection of Autoreactive CD4 T Cells in Brain and Heart Using Major Histocompatibility Complex Class II Dextramers

Published on: August 1, 2014

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...